Find Reports

Select Report Type

Reimbursement Review

Displaying 401 - 425 of 1430

Please scroll or swipe to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Enzalutamide (Xtandi) for Meta...Opens in new tab	Xtandi	Enzalutamide	Enzalutamide (Xtandi) mCSPC – pERC Final Recommendation Opens in new tab Enzalutamide (Xtandi) mCSPC – Final Economic Guidance Report Opens in new tab Enzalutamide (Xtandi) mCSPC – Final Clinical Guidance Report Opens in new tab Enzalutamide (Xtandi) mCSPC – pERC Initial Recommendation Opens in new tab Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial Recommendation Opens in new tab Enzalutamide (Xtandi) mCSPC – Manufacturer Feedback on Initial Recommendation Opens in new tab Enzalutamide (Xtandi) mCSPC – Clinician Feedback on Initial Recommendation Opens in new tab Enzalutamide (Xtandi) mCSPC – Patient Advocacy Group COI Declarations Opens in new tab Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial Recommendation - FeedbackOpens in new tab Enzalutamide (Xtandi) mCSPC – Clinician COI DeclarationsOpens in new tab	mHSPC	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2020	Sep 23, 2020	PC0209-000
Niraparib (Zejula) for Ovarian...Opens in new tab	Zejula	Niraparib	Niraparib (Zejula) OC– pERC Final Recommendation Opens in new tab Niraparib (Zejula) OC– Final Economic Guidance Report Opens in new tab Niraparib (Zejula) OC– Final Clinical Guidance Report Opens in new tab Niraparib (Zejula) for Ovarian Cancer – pERC Initial Recommendation Opens in new tab Niraparib (Zejula) OC– PAG Feedback on Initial Recommendation Opens in new tab Niraparib (Zejula) OC– Manufacturer Feedback on Initial Recommendation Opens in new tab Niraparib (Zejula) OC– Patient Advocacy Group Feedback on Initial Recommendation Opens in new tab Niraparib (Zejula) OC– Clinician Feedback on Initial Recommendation Opens in new tab Niraparib (Zejula) OC– Patient Advocacy Group COI Declarations Opens in new tab Niraparib (Zejula) OC– Clinician COI Declarations Opens in new tab	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 7, 2020	Sep 3, 2020	PC0203-000
caplacizumabOpens in new tab	Cablivi	caplacizumab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Acquired thrombotic thrombocytopenic purpura (aTTP)	Do not reimburse	Complete	Sep 13, 2019	Aug 26, 2020	SR0633-000
eculizumabOpens in new tab	Soliris	eculizumab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Neuromyelitis optica spectrum disorder	Reimburse with clinical criteria and/or conditions	Complete	Feb 25, 2020	Aug 19, 2020	SR0640-000
erenumabOpens in new tab	Aimovig	erenumab	Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Migraine	Reimburse with clinical criteria and/or conditions	Complete	May 2, 2019	Jul 22, 2020	SR0578-000
cabotegravir/rilpivirineOpens in new tab	Vocabria and Cabenuva	cabotegravir sodium cabotegravir-rilpivirine	Recommendation and Reasons Opens in new tab Patient Group Input Submission Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Aug 19, 2019	Jul 22, 2020	SR0628-000
siponimodOpens in new tab	Mayzent	siponimod	Patient Group Input Submissions Opens in new tab Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab	Secondary progressive multiple sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Sep 26, 2019	Jul 21, 2020	SR0631-000
icosapent ethylOpens in new tab	Vascepa	icosapent ethyl	Recommendation and Reasons Opens in new tab Clinical Review Report Opens in new tab Pharmacoeconomic Report Opens in new tab	Ischemic events in statin-treated patients	Reimburse with clinical criteria and/or conditions	Complete	Jun 17, 2019	Jul 16, 2020	SR0619-000
ustekinumabOpens in new tab	Stelara/Stelara I.V	ustekinumab	Patient Group Input Submissions Opens in new tab Recommendation and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab	Ulcerative colitis	Reimburse with clinical criteria and/or conditions	Complete	Aug 12, 2019	Jul 16, 2020	SR0627-000
Tecentriq & Avastin Non-Sq...Opens in new tab	Tecentriq & Avastin	Atezolizumab & Bevacizumab	Atezolizumab-Bevacizumab NSQ-NSCLC – pERC Final Recommendation Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Final Economic Guidance Report Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Final Clinical Guidance Report Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – pERC Initial Recommendation Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – PAG Feedback on Initial Recommendation Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Manufacturer Feedback on Initial Recommendation Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Patient Advocacy Group Feedback on Initial Recommendation Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Clinician Feedback on Initial Recommendation Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Patient Advocacy Group COI Declarations Opens in new tab Atezolizumab-Bevacizumab NSQ-NSCLC – Clinician COI Declarations Opens in new tab	NSQ-NSCLC	Do not reimburse	Complete	Nov 18, 2019	Jul 3, 2020	PC0155-000
glycopyrrolateOpens in new tab	Cuvposa	glycopyrrolate	Recommendation and Reasons Opens in new tab Pharmacoeconomic Report Opens in new tab Clinical Review Report Opens in new tab	chronic severe drooling, neurologic (pediatric)	Do not reimburse	Complete	May 31, 2019	Jun 24, 2020	SR0613-000
Kisqali for Advanced or Metast...Opens in new tab	Kisqali	Ribociclib	Provincial Funding Summary Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC – pERC Final Recommendation Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC – Final Economic Guidance Report Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC – Final Clinical Guidance Report Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC – pERC Initial Recommendation Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC– PAG Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC– Manufacturer Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC– Patient Advocacy Group Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC– Clinician Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC– Patient Advocacy Group COI Declarations Opens in new tab Ribociclib (Kisqali) HR+ HER2- MBC– Clinician COI Declarations Opens in new tab	HR+, HER2- advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2019	Jun 4, 2020	PC0194-000
Brentuximab Vedotin (Adcetris)...Opens in new tab	Adcetris	Brentuximab Vedotin	Provincial Funding Summary Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– pERC Final Recommendation Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Final Economic Guidance Report Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Final Clinical Guidance Report Opens in new tab Brentuximab Vedotin (Adcetris) PTCL – pERC Initial Recommendation Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– PAG Feedback on Initial Recommendation Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Manufacturer Feedback on Initial Recommendation Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Patient Advocacy Group Feedback on Initial Recommendation Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Clinician Feedback on Initial Recommendation Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Patient Advocacy Group COI Declarations Opens in new tab Brentuximab Vedotin (Adcetris) PTCL– Clinician COI Declarations Opens in new tab	peripheral T-cell lymphoma (PTCL)	Reimburse	Complete	Oct 8, 2019	Jun 4, 2020	PC0199-000
naltrexone hydrochloride and b...Opens in new tab	Contrave	naltrexone hydrochloride and bupropion hydrochloride	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Chronic weight management in adults	Do not reimburse	Complete	May 1, 2019	May 27, 2020	SR0610-000
burosumabOpens in new tab	Crysvita	burosumab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Crysvita - Patient Group Input - For posting.pdf Opens in new tab	Treatment of X-Linked Hypophosphatemia	Reimburse with clinical criteria and/or conditions	Complete	Jul 23, 2019	May 27, 2020	SR0602-000
brolucizumabOpens in new tab	Beovu	brolucizumab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Macular degeneration, age-related	Reimburse with clinical criteria and/or conditions	Complete	Sep 26, 2019	May 21, 2020	SR0632-000
Gilteritinib (Xospata) for Acu...Opens in new tab	Xospata	Gilteritinib	Provincial Funding Summary Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – pERC Final Recommendation Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Final Clinical Guidance Report Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Final Economic Guidance Report Opens in new tab Gilteritinib (Xospata) AML – pERC Initial Recommendation Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – PAG Feedback on Initial Recommendation Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Submitter Feedback on Initial Recommendation Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Patient Feedback on Initial Recommendation Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Clinician Feedback on Initial Recommendation Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Patient COI Declarations Opens in new tab Gilteritinib (Xospata) for Acute Myeloid Leukemia – Clinician COI Declarations Opens in new tab		Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2019	May 20, 2020	PC0202 -000
vedolizumabOpens in new tab	Entyvio	vedolizumab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	Ulcerative Colitis	Reimburse with clinical criteria and/or conditions	Complete	Nov 21, 2019	May 19, 2020	SR0635-000
belimumabOpens in new tab	Benlysta	Belimumab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	systemic lupus erythematosus	Do not reimburse	Complete	May 29, 2019	Apr 22, 2020	SR0616-000
Kisqali (with Fulvestrant) for...Opens in new tab	Kisqali	Ribociclib with Fulvestrant	Provincial Funding Summary Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – pERC Final Recommendation Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Final Economic Guidance Report Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Final Clinical Guidance Report Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – pERC Initial Recommendation Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – PAG Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Manufacturer Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Patient Advocacy Group Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Clinician Feedback on Initial Recommendation Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Patient Advocacy Group COI Declarations Opens in new tab Ribociclib (Kisqali) Fulvestrant HR+ HER2- MBC – Clinician COI Declarations (COI Opens in new tab	+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2019	Apr 22, 2020	PC0195-000
Darolutamide (Nubeqa) for Non-...Opens in new tab	Nubeqa	Darolutamide	Darolutamide (Nubeqa) nmCRPC – pERC Final Recommendation Opens in new tab Darolutamide (Nubeqa) nmCRPC – Final Economic Guidance Report Opens in new tab Darolutamide (Nubeqa) nmCRPC – Final Clinical Guidance Report Opens in new tab Darolutamide (Nubeqa) nmCRPC – pERC Initial Recommendation Opens in new tab Darolutamide (Nubeqa) nmCRPC – PAG Feedback on Initial Recommendation Opens in new tab Darolutamide (Nubeqa) nmCRPC – Manufacturer Feedback on Initial Recommendation Opens in new tab Darolutamide (Nubeqa) nmCRPC – Clinician Feedback on Initial Recommendation Opens in new tab Darolutamide (Nubeqa) nmCRPC – Patient Advocacy Group COI Declarations Opens in new tab Darolutamide (Nubeqa) nmCRPC – Clinician COI Declarations Opens in new tab	non-metastatic castration resistant prostate cancer (nmCRPC)	Reimburse with clinical criteria and/or conditions	Complete	Aug 27, 2019	Apr 22, 2020	PC0196-000
Apalutamide (Erleada) for Meta...Opens in new tab	Erleada	Apalutamide	Provincial Funding Summary Opens in new tab Apalutamide (Erleada) mCSPC – pERC Final Recommendation Opens in new tab Apalutamide (Erleada) mCSPC – Final Economic Guidance Report Opens in new tab Apalutamide (Erleada) mCSPC – Final Clinical Guidance Report Opens in new tab Apalutamide (Erleada) mCSPC – pERC Initial Recommendation Opens in new tab Apalutamide (Erleada) mCSPC – PAG Feedback on Initial Recommendation Opens in new tab Apalutamide (Erleada) mCSPC – Manufacturer Feedback on Initial Recommendation Opens in new tab Apalutamide (Erleada) mCSPC – Clinician Feedback on Initial Recommendation Opens in new tab Apalutamide (Erleada) mCSPC – Patient Advocacy Group COI Declarations Opens in new tab Apalutamide (Erleada) mCSPC – Clinician COI Declarations Opens in new tab	metastatic castration-sensitive prostate cancer (mCSPC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 15, 2019	Apr 22, 2020	PC0200-000
Cabozantinib (Cabometyx) for H...Opens in new tab	Cabometyx	Cabozantinib	Cabozantinib (Cabometyx) HCC – pERC Final Recommendation Opens in new tab Cabozantinib (Cabometyx) HCC – Final Economic Guidance Report Opens in new tab Cabozantinib (Cabometyx) HCC – Final Clinical Guidance Report Opens in new tab Cabozantinib (Cabometyx) HCC – pERC Initial Recommendation Opens in new tab Cabozantinib (Cabometyx) HCC – PAG Feedback on Initial Recommendation Opens in new tab Cabozantinib (Cabometyx) HCC – Manufacturer Feedback on Initial Recommendation Opens in new tab 8. Cabozantinib (Cabometyx) HCC – Clinician Feedback on Initial Recommendation Opens in new tab Cabozantinib (Cabometyx) HCC – Patient Advocacy Group COI Declarations Opens in new tab Cabozantinib (Cabometyx) HCC – Clinician COI Declarations Opens in new tab	HCC	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2019	Apr 22, 2020	PC0186-000
dupilumabOpens in new tab	Dupixent	dupilumab	Recommendations and Reasons Opens in new tab Clinical Report Opens in new tab Pharmacoeconomic Report Opens in new tab Patient Group Input Submissions Opens in new tab	atopic dermatitis	Reimburse with clinical criteria and/or conditions	Complete	Oct 22, 2019	Apr 22, 2020	SR0636-000
Pembrolizumab (Keytruda) for R...Opens in new tab	Keytruda	Pembrolizumab	Pembrolizumab (Keytruda) RCC – pERC Final Recommendation Opens in new tab Pembrolizumab (Keytruda) RCC – Final Economic Guidance Report Opens in new tab Pembrolizumab (Keytruda) RCC – Final Clinical Guidance Report Opens in new tab Pembrolizumab (Keytruda) RCC – PAG Feedback on Initial Recommendation Opens in new tab Pembrolizumab (Keytruda) RCC – Manufacturer Feedback on Initial Recommendation Opens in new tab Pembrolizumab (Keytruda) RCC – Clinician Feedback on Initial Recommendation Opens in new tab Pembrolizumab (Keytruda) RCC – Patient Advocacy Group COI Declarations Opens in new tab Pembrolizumab (Keytruda) RCC – Clinician COI Declarations Opens in new tab Pembrolizumab (Keytruda) RCC – pERC Initial RecommendationOpens in new tab	Renal Cell Carcinoma (RCC)	Reimburse with clinical criteria and/or conditions	Complete	Aug 2, 2019	Apr 2, 2020	PC0185-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 401 - 425 of 602

Please scroll or swipe to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Rituximab for the Treatment of Myasthenia Gravis: A 2021 UpdateOpens in new tab	Rituximab for the Treatment of Myasthenia Gravis: A 2021 UpdateOpens in new tab	Apr 19, 2021	Rapid Review		RC1337-000
Urethral Inserts for the Management of Adult Male Urinary IncontinenceOpens in new tab	Urethral Inserts for the Management of Adult Male Urinary IncontinenceOpens in new tab	Apr 16, 2021	Rapid Review	Completed	RC1355-000
Pharmacological Interventions for Vaping CessationOpens in new tab	Pharmacological Interventions for Vaping CessationOpens in new tab	Apr 13, 2021	Summary with Critical Appraisal	Completed	RC1357-000
Models of Care for Chronic Pain: An Environmental ScanOpens in new tab	Models of Care for Chronic Pain: An Environmental Scan Opens in new tab Models of Care for Chronic Pain: Summarizing the EvidenceOpens in new tab	Apr 12, 2021	Environmental Scan	Completed	ES0350-000
Bupropion for Treatment Resistant DepressionOpens in new tab	Bupropion for Treatment Resistant Depression Opens in new tab	Apr 12, 2021	Summary with Critical Appraisal	Completed	RC1351-000
Lenses and Spectacles to Prevent Myopia Worsening in ChildrenOpens in new tab	Lenses and Spectacles to Prevent Myopia Worsening in Children Opens in new tab	Apr 9, 2021	Summary with Critical Appraisal		RC1349-000
Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote SettingsOpens in new tab	Interferon Gamma Release Assay for the Identification of Latent Tuberculosis Infection in Rural and Remote Settings Opens in new tab	Apr 9, 2021	Summary with Critical Appraisal	Completed	RC1341-000
Flash Glucose Monitoring Systems in Pediatric Populations with DiabetesOpens in new tab	Flash Glucose Monitoring Systems in Pediatric Populations with Diabetes Opens in new tab	Apr 6, 2021	Summary with Critical Appraisal	Completed	RC1354-000
COVID-19 Impact on Intimate Partner Violence and Child MaltreatmentOpens in new tab	COVID-19 Impact on Intimate Partner Violence and Child MaltreatmentOpens in new tab	Mar 30, 2021			CI0145-000
Point-of-Care Testing of International Normalized Ratios for People on Oral Anticoagulants: A Rapid Qualitative ReviewOpens in new tab	Point-of-Care Testing of International Normalized Ratios for People on Oral Ant…Opens in new tab	Mar 30, 2021	Summary with Critical Appraisal	Completed	RC1334-000
Treatment Sequences of Androgen Receptor Targeted Agents for Patients with Prostate CancerOpens in new tab	Summary With Critical Appraisal - Rapid Response ReportOpens in new tab	Mar 17, 2021	Summary with Critical Appraisal	Completed	RC1347-000
Remote Monitoring Programs for Cardiac Conditions in CanadaOpens in new tab		Mar 12, 2021	Environmental Scan	Completed	ES0345-000
Interventions to influence the use of antibiotics for acute upper respiratory tract infectionsOpens in new tab	Interventions to influence the use of antibiotics for acute upper respiratory t…Opens in new tab	Mar 12, 2021	Summary with Critical Appraisal		RC1332-000
Onabotulinum Toxin A for Spasticity Associated with Multiple SclerosisOpens in new tab	Onabotulinum Toxin A for Spasticity Associated with Multiple SclerosisOpens in new tab	Mar 11, 2021	Summary with Critical Appraisal		RC1340-000
Remote Monitoring Programs for Cardiac Conditions in CanadaOpens in new tab		Mar 11, 2021	Environmental Scan		ES0345-000
Stellate Ganglion Block for the Treatment of Post-Traumatic Stress Disorder, Depression, and AnxietyOpens in new tab	Stellate Ganglion Block for the Treatment of Post-Traumatic Stress Disorder, Depression, and Anxiety Opens in new tab	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1339-000
Codeine for Pain Related to Caesarean Section: A Review of Clinical EffectivenessOpens in new tab	Codeine for Pain Related to Caesarean Section: A Review of Clinical Effectiveness Opens in new tab	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1326-000
Codeine for Acute Dental Pain and Acute Pain Related to Dental ProceduresOpens in new tab	Codeine for Acute Dental Pain and Acute Pain Related to Dental Procedures Opens in new tab	Mar 3, 2021	Summary with Critical Appraisal	Completed	RC1325-000
Yttrium 90 Microspheres for Advanced, Recurrent, or Inoperable Hepatocellular Carcinoma: A Review of Clinical and Cost EffectivenessOpens in new tab	Yttrium 90 Microspheres for Advanced, Recurrent, or Inoperable Hepatocellular Carcinoma: A Review of Clinical and Cost Effectiveness Opens in new tab	Mar 1, 2021	Rapid Review with Expert Input	Completed	RD0059-000
Patient Navigation Programs for People With DementiaOpens in new tab	Patient Navigation Programs for People With DementiaOpens in new tab	Feb 24, 2021	Summary with Critical Appraisal	Completed	RC1333-000
Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-EffectivenessOpens in new tab	Rapid Testing for the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance: A Review of Cost-Effectiveness Opens in new tab	Feb 19, 2021	Summary with Critical Appraisal	Completed	RC1328-000
Incentives and Support Programs to Improve Adherence to Tuberculosis TreatmentOpens in new tab	Incentives and Support Programs to Improve Adherence to Tuberculosis Treatment Opens in new tab	Feb 18, 2021	Summary with Critical Appraisal	Completed	RC1318-000
Rituximab for the Treatment of Neuromyelitis Optica Spectrum DisorderOpens in new tab	Rituximab for the Treatment of Neuromyelitis Optica Spectrum Disorder (Peer-re…Opens in new tab	Feb 9, 2021	Peer-reviewed Summary with Critical Appraisal		RD0058-000
Gravity Drainage Versus Forced Suction Drainage for Patients With Excess Fluid in Pleural or Peritoneal SpacesOpens in new tab	Gravity Drainage Versus Forced Suction Drainage for Patients With Excess Fluid in Pleural or Peritoneal Spaces Opens in new tab	Feb 8, 2021	Summary with Critical Appraisal		RC1327-000
Workplace Electronic Health Promotion Campaigns for Tobacco Smoking Prevention or Cessation: A Review of Cost-EffectivenessOpens in new tab	Workplace Electronic Health Promotion Campaigns for Tobacco Smoking Prevention …Opens in new tab	Feb 2, 2021	Summary with Critical Appraisal	Completed	RC1335-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1 - 25 of 25

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 401 - 425 of 2142

Please scroll or swipe to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
dexamethasone intravitreal implantOpens in new tab		Recommendation and ReasonsOpens in new tab Clinical and Pharmacoeconomic combined ReportOpens in new tab Stakeholder feedback on Draft RecommendationOpens in new tab	Jul 23, 2024	Reimbursement Review		Complete	SR0739-000
upadacitinibOpens in new tab		Recommendation and ReasonsOpens in new tab Clinical and Pharmacoeconomic combined ReportOpens in new tab Stakeholder feedback on Draft RecommendationOpens in new tab	Jul 23, 2024	Reimbursement Review		Complete	SR0730-000
Auditory Verbal Therapy for Children with Hearing Loss Opens in new tab		Auditory Verbal Therapy for Children with Hearing Loss Opens in new tab	Jul 19, 2024	Health Technology Review	Rapid Review	Completed	RC1542-000
Optimizing ultrasound booking schedulesOpens in new tab			Jul 16, 2024	Health Technology Review		In Progress	CM0021-000
SomatropinOpens in new tab		Final ReportOpens in new tab	Jul 12, 2024	Health Technology Review	Technology Review	Completed	HC0068-000
Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator TherapyOpens in new tab	Our utilization analysis examines the market share and drug expenditures of targeted immune modulators for inflammatory bowel disease across public drug plans in Canada.	Final ReportOpens in new tab	Jul 11, 2024	Health Technology Review	Technology Review	Complete	HC0063-000
fidaxomicinOpens in new tab			Jul 11, 2024	Reimbursement Review		Withdrawn	SF0847-000
nirmatrelvir/ritonavir Opens in new tab		Recommendation and ReasonsOpens in new tab Patient and Clinician Group input Opens in new tab Clinical and Pharmacoeconomic Combined ReportOpens in new tab Stakeholder feedback on Draft RecommendationOpens in new tab	Jul 9, 2024	Reimbursement Review		Complete	SR0808-000
Appraisal of RWE submitted for health technology assessmentOpens in new tab			Jun 28, 2024	Health Technology Review		In Progress	MG0028-000
PET-CT Comparisons 2020-2024Opens in new tab			Jun 28, 2024	Health Technology Review		In Progress	CM0006-000
Cystic FibrosisOpens in new tab			Jun 28, 2024	Health Technology Review		In Progress	HM0005-000
Natural Cycles App as ContraceptionOpens in new tab			Jun 28, 2024	Horizon Scan	Health Technology Update	In Progress	EN0057-000
Newborn screening - Drugs for Rare Diseases StrategyOpens in new tab			Jun 28, 2024	Health Technology Review	Technology Review	In Progress	HC0079-000
Methodology for Ethics Analysis in Pharmaceutical Reimbursement ReviewsOpens in new tab			Jun 28, 2024	Health Technology Review		In Progress	MG0027-000
Pharmaceutical Reviews Update — Issue 48Opens in new tab			Jun 27, 2024	Reimbursement Review	Pharmaceutical Review Update
Endometrial CancerOpens in new tab		Final ReportOpens in new tab	Jun 27, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0045-000
NSCLC without actionable oncogenic alterationOpens in new tab		Final ReportOpens in new tab	Jun 27, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0046-000
cannabidiol Opens in new tab		Recommendation and ReasonsOpens in new tab Patient and Clinician Group InputOpens in new tab Clinical and Pharmacoeconomic Combined ReportOpens in new tab Stakeholder feedback on Draft RecommendationOpens in new tab	Jun 27, 2024	Reimbursement Review		Complete	SR0799-000
Choline Supplementation for Infants, Children, and Pregnant PeopleOpens in new tab		Choline Supplementation for Infants, Children, and Pregnant People Opens in new tab	Jun 18, 2024	Health Technology Review	Rapid Review	Completed	RC1531-000
Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated SyndromeOpens in new tab		Interferons, Glatiramer Acetate, and Minocycline for Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome Opens in new tab	Jun 17, 2024	Health Technology Review	Rapid Review	Completed	RC1540-000
Nabilone for Chronic Non-Cancer PainOpens in new tab		Nabilone for Chronic Non-Cancer Pain Opens in new tab	Jun 14, 2024	Health Technology Review	Rapid Review	Completed	RC1539-000
Infliximab for Immune Checkpoint Inhibitor Therapy-Related ToxicitiesOpens in new tab		Infliximab for Immune Checkpoint Inhibitor Therapy-Related Toxicities Opens in new tab	Jun 14, 2024	Health Technology Review	Rapid Review	Completed	RC1536-000
ravulizumab Opens in new tab		Recommendation and ReasonsOpens in new tab Patient and Clinician Group input Opens in new tab Clinical and Pharmacoeconomic Combined ReportOpens in new tab Stakeholder feedback on Draft RecommendationOpens in new tab	Jun 14, 2024	Reimbursement Review		Complete	SR0785-000
Minimum Retesting Intervals for Lab TestsOpens in new tab	Canada’s Drug Agency partnered with Choosing Wisely Canada to host a multidisciplinary panel of experts to provide guidance on the minimum retesting intervals of laboratory tests that are commonly repeated in hospitals, health authorities, and community laboratories across the country.	Final Guidance ReportOpens in new tab Technology Review - Minimum Retesting Intervals for Lab TestsOpens in new tab Lipase Quick GuideOpens in new tab Hemoglobin A1C Quick GuideOpens in new tab Thyroid Stimulating Hormone Quick GuideOpens in new tab Serum Protein Electrophoresis Quick GuideOpens in new tab Antinuclear Antibody Quick GuideOpens in new tab	Jun 11, 2024	Health Technology Review	Technology Review	Completed	HC0078-000
treosulfan Opens in new tab		Recommendation and ReasonsOpens in new tab Clinical, Pharmacoeconomic and Ethics combined ReportOpens in new tab Stakeholder feedback on Draft RecommendationOpens in new tab	Jun 10, 2024	Reimbursement Review		Complete	PC0324-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81